Department of Internal Medicine, Zuyderland Medical Centre, Sittard/Heerlen, The Netherlands.
Department of Radiology, Zuyderland Medical Centre, Sittard/Heerlen, The Netherlands.
PLoS One. 2023 Mar 23;18(3):e0283459. doi: 10.1371/journal.pone.0283459. eCollection 2023.
Diagnosing concomitant pulmonary embolism (PE) in COVID-19 patients remains challenging. As such, PE may be overlooked. We compared the diagnostic yield of systematic PE-screening based on the YEARS-algorithm to PE-screening based on clinical gestalt in emergency department (ED) patients with COVID-19.
We included all ED patients who were admitted because of COVID-19 between March 2020 and February 2021. Patients already receiving anticoagulant treatment were excluded. Up to April 7, 2020, the decision to perform CT-pulmonary angiography (CTPA) was based on physician's clinical gestalt (clinical gestalt cohort). From April 7 onwards, systematic PE-screening was performed by CTPA if D-dimer level was ≥1000 ug/L, or ≥500 ug/L in case of ≥1 YEARS-item (systematic screening cohort).
1095 ED patients with COVID-19 were admitted. After applying exclusion criteria, 289 were included in the clinical gestalt and 574 in the systematic screening cohort. The number of PE diagnoses was significantly higher in the systematic screening cohort compared to the clinical gestalt cohort: 8.2% vs. 1.0% (3/289 vs. 47/574; p<0.001), even after adjustment for differences in patient characteristics (adjusted OR 8.45 (95%CI 2.61-27.42, p<0.001) for PE diagnosis). In multivariate analysis, D-dimer (OR 1.09 per 1000 μg/L increase, 95%CI 1.06-1.13, p<0.001) and CRP >100 mg/L (OR 2.78, 95%CI 1.37-5.66, p = 0.005) were independently associated with PE.
In ED patients with COVID-19, the number of PE diagnosis was significantly higher in the cohort that underwent systematic PE screening based on the YEARS-algorithm in comparison with the clinical gestalt cohort, with a number needed to test of 7.1 CTPAs to detect one PE.
在 COVID-19 患者中诊断合并肺栓塞(PE)仍然具有挑战性。因此,PE 可能会被忽视。我们比较了基于 YEARS 算法的系统 PE 筛查与急诊科(ED)COVID-19 患者基于临床判断的 PE 筛查的诊断效果。
我们纳入了 2020 年 3 月至 2021 年 2 月因 COVID-19 住院的所有 ED 患者。排除已接受抗凝治疗的患者。截至 2020 年 4 月 7 日,根据医生的临床判断(临床判断队列)决定是否进行 CT 肺动脉造影(CTPA)。从 2020 年 4 月 7 日起,如果 D-二聚体水平≥1000μg/L,或有≥1 个 YEARS 项目(系统筛查队列)时≥500μg/L,则进行系统的 PE 筛查。
共纳入 1095 例 COVID-19 住院 ED 患者。排除标准后,289 例纳入临床判断队列,574 例纳入系统筛查队列。与临床判断队列相比,系统筛查队列中 PE 诊断的数量明显更高:8.2%比 1.0%(3/289 比 47/574;p<0.001),即使调整了患者特征的差异(调整后的 OR 8.45(95%CI 2.61-27.42,p<0.001))。多变量分析显示,D-二聚体(每增加 1000μg/L,OR 1.09,95%CI 1.06-1.13,p<0.001)和 CRP>100mg/L(OR 2.78,95%CI 1.37-5.66,p=0.005)与 PE 独立相关。
在 COVID-19 的 ED 患者中,与基于临床判断的筛查相比,基于 YEARS 算法的系统 PE 筛查的队列中 PE 诊断数量明显更高,需要进行 7.1 次 CTPA 检测才能发现 1 例 PE。